These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 37322038)
21. Parkinson disease and incidental Lewy body disease: Just a question of time? Iacono D; Geraci-Erck M; Rabin ML; Adler CH; Serrano G; Beach TG; Kurlan R Neurology; 2015 Nov; 85(19):1670-9. PubMed ID: 26468408 [TBL] [Abstract][Full Text] [Related]
22. VMAT2 availability in Parkinson's disease with probable REM sleep behaviour disorder. Valli M; Cho SS; Uribe C; Masellis M; Chen R; Mihaescu A; Strafella AP Mol Brain; 2021 Nov; 14(1):165. PubMed ID: 34758845 [TBL] [Abstract][Full Text] [Related]
23. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Frigerio R; Fujishiro H; Ahn TB; Josephs KA; Maraganore DM; DelleDonne A; Parisi JE; Klos KJ; Boeve BF; Dickson DW; Ahlskog JE Neurobiol Aging; 2011 May; 32(5):857-63. PubMed ID: 19560232 [TBL] [Abstract][Full Text] [Related]
24. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Wilson JM; Levey AI; Rajput A; Ang L; Guttman M; Shannak K; Niznik HB; Hornykiewicz O; Pifl C; Kish SJ Neurology; 1996 Sep; 47(3):718-26. PubMed ID: 8797470 [TBL] [Abstract][Full Text] [Related]
25. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? Boileau I; Rusjan P; Houle S; Wilkins D; Tong J; Selby P; Guttman M; Saint-Cyr JA; Wilson AA; Kish SJ J Neurosci; 2008 Sep; 28(39):9850-6. PubMed ID: 18815269 [TBL] [Abstract][Full Text] [Related]
26. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521 [TBL] [Abstract][Full Text] [Related]
27. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406 [TBL] [Abstract][Full Text] [Related]
28. Chronic exposure to dopamine agonists affects the integrity of striatal D Politis M; Wilson H; Wu K; Brooks DJ; Piccini P Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087 [TBL] [Abstract][Full Text] [Related]
29. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909 [TBL] [Abstract][Full Text] [Related]
30. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365 [TBL] [Abstract][Full Text] [Related]
31. Longitudinal striatal dopamine transporter binding and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in Parkinson's disease. Nabizadeh F; Pirahesh K; Ramezannezhad E Neurol Sci; 2023 Feb; 44(2):573-585. PubMed ID: 36227385 [TBL] [Abstract][Full Text] [Related]
33. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035 [TBL] [Abstract][Full Text] [Related]
34. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Milber JM; Noorigian JV; Morley JF; Petrovitch H; White L; Ross GW; Duda JE Neurology; 2012 Dec; 79(24):2307-14. PubMed ID: 23152586 [TBL] [Abstract][Full Text] [Related]
35. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102 [TBL] [Abstract][Full Text] [Related]